AzTrials
AzTrials

Anxiety DepressionNCT05911412

Development of the Neuroimaging Biomarker-based Prediction Model of Anxiety-related Disorders: Effect of Mindfulness-based Cognitive Therapy Using Neuroscience on the Brain

A study testing Mindfulness-based cognitive therapy using neuroscience (NMBCT) in people with Anxiety Depression, run by CHA University.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The purpose of this study designed a randomized clinical trial is to determine the efficacy of an 8-week mindfulness-based cognitive therapy using neuroscience (NMBCT) to reduce anxiety or depressive symptoms among adult participants with anxiety and depression. Read more about this study

Who is it for?
Ages 19 years and olderHealthy volunteers can take part
Conditions the study is for
Anxiety Depression
What is being tested?
Mindfulness-based cognitive therapy using neuroscience (NMBCT)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
64 participants
Where
No sites listed yet
Study dates
1 Sep 2023to 31 Dec 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 19 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • over 19 years of age
  • a Beck Depression Inventory score of more than 5 but less than 20 points
  • a Beck Anxiety Inventory score of more than 5 but less than 25 points
  • A person who has been sufficiently explained and understood the contents of clinical trials, and maintains the ability to make a free-will decision
  • Those with normal or normal corrected vision
  • Those without claustrophobic symptoms
  • Right-handed person
  • Those who do not have a family history of psychiatric disease in the first family (parents, children, siblings)

Who cannot join

  • Currently taking psychoactive drugs
  • Those with a history of neurological disease, head trauma with loss of consciousness, or mental retardation (IQ <70)
  • A person who currently requires hospitalization due to a serious physical illness or who has not passed 6 months since discharge
  • Pregnant and lactating women
  • A person who is judged to be at risk of serious suicide or violent behavior in a mental status examination
  • A person who is judged to have severe symptoms or significant decline in reality testing and judgment through a mental status examination by a psychiatrist
Show all 10Show fewer
  • Foreigners
  • Those who are illiterate in Korean
  • Those who have previously received mindfulness-based cognitive therapy
  • If the researcher judges that the researcher is unsuitable for participation in clinical trials due to other reasons

Trial locations and contacts

No sites are listed yet.

Hyun-Ju Kim, MD., PhD contact

82+31-780-5874

guswn10ve@gmail.com

Hye-Yeon Jung, MA contact

hychung980607@gmail.com

About this study

Official title: Development of the Neuroimaging Biomarker-based Prediction Model of Anxiety-related Disorders and Novel Treatment Strategies: Effect of Mindfulness-based Cognitive Therapy Using Neuroscience on the Brain

The purpose of this study designed a randomized clinical trial is to determine the efficacy of an 8-week mindfulness-based cognitive therapy using neuroscience (NMBCT) to reduce anxiety or depressive symptoms among adult participants with anxiety and depression. The primary object is to assess the effectiveness of NMBCT to change in the structural or functional brain. A secondary objective is to reduce clinical symptom severity.

Read the detailed description

There are reports that mindfulness-based cognitive therapy (MBCT) techniques in patients with panic disorder or depression promote neuroplasticity changes in the brain, thereby restoring individual vulnerability to anxiety. This clinical study aims to develop a metacognitive task that improves existing MBCT as a new treatment that changes the function of anxiety or depression-specific neural circuits, and to explore neurological mechanisms and treatment-related factors.

This study was designed to enroll 64 participants, 32 in the NMBCT intervention and 32 in waitlist. This will allow 20% attrition and the Investigators anticipate 52 participants will complete the study. A sample size of 52 will achieve 80% power, given current effect size (cohen's d = 0.40, alpha = 0.05) estimates per aim.

Participants randomized to the NMBCT intervention or waitlist group will complete an 8-week NMBCT program conducted by a trained psychiatrist. The waitlist control group will maintain the blind for a treatment period from the baseline and then implement the NMBCT program on the NMBCT intervention group to those who agree.

Study data will be collected at 3 times for two groups: T1=1st week session (baseline); T2=8th week session; T3=6 months after baseline. All participants in the clinical study will undergo a total of two brain MRI tests within two weeks before and after visit 2 (T1, baseline) and visit 3 (T2, post-treatment, 8 weeks later).

Being tested
Mindfulness-based cognitive therapy using neuroscience (NMBCT)
Keywords
mindfulness-based cognitive therapy, mri, neuroscience

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Mindfulness-based cognitive therapy using neuroscience (NMBCT)Behavioural

    Mindfulness-based cognitive therapy using neuroscience (NMBCT) is a standardized 8-week course taught by trained instructors. The NMBCT is a group therapy that takes place once a week for about 90 minutes per session. The program consists of mental education for each session, 2-3 mindfulness meditation practice, mindfulness practice in daily life, and about 30 minutes of daily home mindfulness meditation task. While participating in the program, the subjects will receive psychoeducation and various mindfulness meditation techniques (eating meditation, breathing meditation, sedentary meditation, viewing meditation, and listening meditation, etc.).

Study groups in NCT05911412
Study groupRoleWhat they receive
NMBCT interventionExperimentalParticipants in this arm enter the 8-week NMBCT course immediately after the baseline visit.
Receives: Behavioral: Mindfulness-based cognitive therapy using neuroscience (NMBCT)
WaitlistExperimentalParticipants in the waitlist control arm will wait for 8 weeks after the baseline visit, and then will be offered an identical 8-week NMBCT course.
Receives: Behavioral: Mindfulness-based cognitive therapy using neuroscience (NMBCT)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in GMV measured with sMRI

    Change in gray matter volume (GMV) in mm3 measured with structural MRI (sMRI)

    Measured: baseline, 8 weeks after treatment

  2. Change in CT measured with sMRI

    Change in cortical thickness (CT) in mm measured with structural MRI (sMRI)

    Measured: baseline, 8 weeks after treatment

  3. Change in SA measured with sMRI

    Change in surface area (SA) in mm2 measured with structural MRI (sMRI)

    Measured: baseline, 8 weeks after treatment

  4. Change LGI measured with sMRI

    Change in local gyrification index (LGI), ranged from 0 to 1, measured with structural MRI (sMRI)

    Measured: baseline, 8 weeks after treatment

  5. Change in FA measured with DTI

    Change in fractional anisotropy (FA), ranged from 0 to 1, measured with diffusion tensor imaging (DTI) and T1-weighted MR image.

    Measured: baseline, 8 weeks after treatment

  6. Change in MD measured with DTI

    Change in mean diffusivity (MD), ranged from 0 to 1, measured with diffusion tensor imaging (DTI) and T1-weighted MR image.

    Measured: baseline, 8 weeks after treatment

  7. Change in AD measured with DTI

    Change in axial diffusivity (AD), ranged from 0 to 1, measured with diffusion tensor imaging (DTI) and T1-weighted MR image.

    Measured: baseline, 8 weeks after treatment

  8. Change in RD measured with DTI

    Change in radial diffusivity (AD), ranged from 0 to 1, measured with diffusion tensor imaging (DTI) and T1-weighted MR image.

    Measured: baseline, 8 weeks after treatment

  9. Change in FC measured with fMRI

    Change in functional connectivity (FC) in resting-state functional MRI (fMRI).

    Measured: baseline, 8 weeks after treatment

Secondary outcomes (11)

  1. The changes in the Korean version of Panic Disorder Severity Scale (PDSS).

    To assess panic symptom changes after the 8th week of treatment using the Korean version of the Panic Disorder Severity Scale (PDSS). The PDSS consists of 7 items coded on a 5-point scale (0-4). The total scores ranged from 0 to 28. The higher the total scores, the higher the panic symptom severity.

    Measured: baseline, 8 week after treatment

  2. The change in the Korean version of Albany Panic and Phobia Questionnaire (APPQ)

    To assess agoraphobia symptoms changes after the 8th week of treatment, the Korean Albany Panic and Phobia Questionnaire (APPQ) was used. The APPQ contains 27 items coded on a 9-point scale (0-8). And it can be used to assess interoceptive fear (8 items), social phobia (10 items), and agoraphobia (9 items). The higher each subscale's total score, the poorer the phobic symptom.

    Measured: baseline, 8 week after treatment

  3. The change in the Korean version of the Beck Depression Inventory (BDI)-II

    To assess depressive symptoms changes after the 8th week of treatment, the Beck Depression Inventory (BDI)-II was used. The 21 self-administered items that comprise the BDI-II were scored from a range of 0 to 3, with the maximum score being 63. The higher the total scores, the more severe the depressive symptom.

    Measured: baseline, 8 week after treatment

  4. The change in the Korean version of the Beck Anxiety Inventory (BAI)

    To assess anxiety symptoms changes after the 8th week of treatment, the Beck Anxiety Inventory (BAI) was used. The 21 self-administered items that comprise the BAI were scored from a range of 0 to 3, with the maximum score being 63. The higher the total scores, the more severe the anxiety symptom.

    Measured: baseline, 8 week after treatment

  5. The change in the Korean version of the Penn State Worry Questionnaire (PSWQ)

    To assess the frequency, intensity, and uncontrollability of pathological worry symptoms changes after the 8th week of treatment, the Penn State Worry Questionnaire (PSWQ) was used. The 16 self-administered items that comprise the PSWQ were scored from a range of 1 (not at all typical) to 5 (very typical), with the maximum score being 80. The higher the total scores, the more severe the pathological worry symptom.

    Measured: baseline, 8 week after treatment

  6. The change in the Korean version of the Anxiety Sensitivity Inventory-Revised (ASI-R)

    To assess the trait anxiety sensitivity levels changes after the 8th week of treatment, the Korean version of the Anxiety Sensitivity Inventory-Revised (ASI-R) was used. The 36-item ASI-R consists of (1) fear of respiratory symptoms, (2) publicly observable anxiety reactions, (3) cardiovascular symptoms, and (4) cognitive dyscontrol. Total scores range from 0 to 144. The higher the total scores, the higher the anxiety sensitivity levels.

    Measured: baseline, 8 week after treatment

  7. The change in the Self-Compassion Scale-Short Form (SCS-SF)

    To assess the changes in self-compassion levels after the 8th week of treatment, the Self-Compassion Scale-Short Form (SCS-SF) was used. The 12-item SCS-SF consists of self-kindness (2 items), self-judgment (2 items), common humanity (2 items), isolation subscales (2 items), mindfulness (2 items), and over-identified (2 items). Total scores range from 12 to 60. The reverse score of the negative subscale items (e.g., self-judgment, isolation, and over-identification) was used to compute total self-compassion scores. The higher the total scores, the higher the self-compassion levels.

    Measured: baseline, 8 week after treatment

  8. The change in the Concise Measure of Subjective Well-Being (COMOSWB)

    To evaluate the changes in subjective well-being levels after the 8th week of treatment, the Concise Measure of Subjective Well-Being (COMOSWB) was used. The COMOSWB consists of life satisfaction, positive affect, and negative affect. The 9-item was scored from a range of 1 (strongly disagree or never) to 7 (strongly agree or always). Total scores range from 7 to 63. The higher the total scores, the higher the subjective well-being levels.

    Measured: baseline, 8 week after treatment

  9. The change in the Korean Burnout Syndrome Scale (KBOSS)

    To evaluate the changes in burnout symptoms levels after the 8th week of treatment, the Korean Burnout Syndrome Scale (KBOSS) was used. The 12-item KBOSS consists of exhaustion (4 items), cynicism (4 items), and inefficacy (4 items). The 16-item was scored from a range of 1 (strongly disagree) to 7 (strongly agree), with the maximum score being 84. Total scores range from 12 to 84. The higher the total scores, the more severe the burn-out symptom.

    Measured: baseline, 8 week after treatment

  10. The change in the Korean version of the Grit Scale

    To evaluate the changes in grit levels after the 8th week of treatment, the Korean version of the Grit Scale was used. The 12-item of the Korean version of the Grit scale was scored from a range of 0 (strongly disagree) to 5 (strongly agree), with the maximum score being 60. The higher the total scores, the higher levels of grit.

    Measured: baseline, 8 week after treatment

  11. side effects

    To evaluate the side effects through the interview

    Measured: baseline, 2 week/4 week/8 week after treatment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Jun 2023
  2. Study start1 Sep 2023 (estimated)
  3. Primary completion28 Feb 2024 (estimated)
  4. Study completion31 Dec 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
64 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05911412
Sponsor's protocol ID
2022-10-041-002
Status last verified
Aug 2023
First submitted
23 Feb 2023
Last updated
25 Aug 2023
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Guendelman S, Bayer M, Prehn K, Dziobek I. Towards a mechanistic understanding of mindfulness-based stress reduction (MBSR) using an RCT neuroimaging approach: Effects on regulating own stress in social and non-social situations. Neuroimage. 2022 Jul 1;254:119059. doi: 10.1016/j.neuroimage.2022.119059. Epub 2022 Mar 5.

    PubMed 35259523

  • Yun JY, Boedhoe PSW, Vriend C, Jahanshad N, Abe Y, Ameis SH, Anticevic A, Arnold PD, Batistuzzo MC, Benedetti F, Beucke JC, Bollettini I, Bose A, Brem S, Calvo A, Cheng Y, Cho KIK, Ciullo V, Dallaspezia S, Denys D, Feusner JD, Fouche JP, Gimenez M, Gruner P, Hibar DP, Hoexter MQ, Hu H, Huyser C, Ikari K, Kathmann N, Kaufmann C, Koch K, Lazaro L, Lochner C, Marques P, Marsh R, Martinez-Zalacain I, Mataix-Cols D, Menchon JM, Minuzzi L, Morgado P, Moreira P, Nakamae T, Nakao T, Narayanaswamy JC, Nurmi EL, O'Neill J, Piacentini J, Piras F, Piras F, Reddy YCJ, Sato JR, Simpson HB, Soreni N, Soriano-Mas C, Spalletta G, Stevens MC, Szeszko PR, Tolin DF, Venkatasubramanian G, Walitza S, Wang Z, van Wingen GA, Xu J, Xu X, Zhao Q; ENIGMA-OCD working group; Thompson PM, Stein DJ, van den Heuvel OA, Kwon JS. Brain structural covariance networks in obsessive-compulsive disorder: a graph analysis from the ENIGMA Consortium. Brain. 2020 Feb 1;143(2):684-700. doi: 10.1093/brain/awaa001.

    PubMed 32040561

  • Yook K, Lee SH, Ryu M, Kim KH, Choi TK, Suh SY, Kim YW, Kim B, Kim MY, Kim MJ. Usefulness of mindfulness-based cognitive therapy for treating insomnia in patients with anxiety disorders: a pilot study. J Nerv Ment Dis. 2008 Jun;196(6):501-3. doi: 10.1097/NMD.0b013e31817762ac.

    PubMed 18552629

  • Williams LM. Precision psychiatry: a neural circuit taxonomy for depression and anxiety. Lancet Psychiatry. 2016 May;3(5):472-80. doi: 10.1016/S2215-0366(15)00579-9. Epub 2016 Apr 14.

    PubMed 27150382

  • Varghese B, Chen F, Hwang D, Palmer SL, De Castro Abreu AL, Ukimura O, Aron M, Aron M, Gill I, Duddalwar V, Pandey G. Objective risk stratification of prostate cancer using machine learning and radiomics applied to multiparametric magnetic resonance images. Sci Rep. 2019 Feb 7;9(1):1570. doi: 10.1038/s41598-018-38381-x.

    PubMed 30733585

  • Tang YY, Holzel BK, Posner MI. The neuroscience of mindfulness meditation. Nat Rev Neurosci. 2015 Apr;16(4):213-25. doi: 10.1038/nrn3916. Epub 2015 Mar 18.

    PubMed 25783612

  • Stein JL, Medland SE, Vasquez AA, Hibar DP, Senstad RE, Winkler AM, Toro R, Appel K, Bartecek R, Bergmann O, Bernard M, Brown AA, Cannon DM, Chakravarty MM, Christoforou A, Domin M, Grimm O, Hollinshead M, Holmes AJ, Homuth G, Hottenga JJ, Langan C, Lopez LM, Hansell NK, Hwang KS, Kim S, Laje G, Lee PH, Liu X, Loth E, Lourdusamy A, Mattingsdal M, Mohnke S, Maniega SM, Nho K, Nugent AC, O'Brien C, Papmeyer M, Putz B, Ramasamy A, Rasmussen J, Rijpkema M, Risacher SL, Roddey JC, Rose EJ, Ryten M, Shen L, Sprooten E, Strengman E, Teumer A, Trabzuni D, Turner J, van Eijk K, van Erp TG, van Tol MJ, Wittfeld K, Wolf C, Woudstra S, Aleman A, Alhusaini S, Almasy L, Binder EB, Brohawn DG, Cantor RM, Carless MA, Corvin A, Czisch M, Curran JE, Davies G, de Almeida MA, Delanty N, Depondt C, Duggirala R, Dyer TD, Erk S, Fagerness J, Fox PT, Freimer NB, Gill M, Goring HH, Hagler DJ, Hoehn D, Holsboer F, Hoogman M, Hosten N, Jahanshad N, Johnson MP, Kasperaviciute D, Kent JW Jr, Kochunov P, Lancaster JL, Lawrie SM, Liewald DC, Mandl R, Matarin M, Mattheisen M, Meisenzahl E, Melle I, Moses EK, Muhleisen TW, Nauck M, Nothen MM, Olvera RL, Pandolfo M, Pike GB, Puls R, Reinvang I, Renteria ME, Rietschel M, Roffman JL, Royle NA, Rujescu D, Savitz J, Schnack HG, Schnell K, Seiferth N, Smith C, Steen VM, Valdes Hernandez MC, Van den Heuvel M, van der Wee NJ, Van Haren NE, Veltman JA, Volzke H, Walker R, Westlye LT, Whelan CD, Agartz I, Boomsma DI, Cavalleri GL, Dale AM, Djurovic S, Drevets WC, Hagoort P, Hall J, Heinz A, Jack CR Jr, Foroud TM, Le Hellard S, Macciardi F, Montgomery GW, Poline JB, Porteous DJ, Sisodiya SM, Starr JM, Sussmann J, Toga AW, Veltman DJ, Walter H, Weiner MW; Alzheimer's Disease Neuroimaging Initiative; EPIGEN Consortium; IMAGEN Consortium; Saguenay Youth Study Group; Bis JC, Ikram MA, Smith AV, Gudnason V, Tzourio C, Vernooij MW, Launer LJ, DeCarli C, Seshadri S; Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium; Andreassen OA, Apostolova LG, Bastin ME, Blangero J, Brunner HG, Buckner RL, Cichon S, Coppola G, de Zubicaray GI, Deary IJ, Donohoe G, de Geus EJ, Espeseth T, Fernandez G, Glahn DC, Grabe HJ, Hardy J, Hulshoff Pol HE, Jenkinson M, Kahn RS, McDonald C, McIntosh AM, McMahon FJ, McMahon KL, Meyer-Lindenberg A, Morris DW, Muller-Myhsok B, Nichols TE, Ophoff RA, Paus T, Pausova Z, Penninx BW, Potkin SG, Samann PG, Saykin AJ, Schumann G, Smoller JW, Wardlaw JM, Weale ME, Martin NG, Franke B, Wright MJ, Thompson PM; Enhancing Neuro Imaging Genetics through Meta-Analysis Consortium. Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet. 2012 Apr 15;44(5):552-61. doi: 10.1038/ng.2250.

    PubMed 22504417

  • Sun H, Chen Y, Huang Q, Lui S, Huang X, Shi Y, Xu X, Sweeney JA, Gong Q. Psychoradiologic Utility of MR Imaging for Diagnosis of Attention Deficit Hyperactivity Disorder: A Radiomics Analysis. Radiology. 2018 May;287(2):620-630. doi: 10.1148/radiol.2017170226. Epub 2017 Nov 22.

    PubMed 29165048

  • Shear MK, Bjelland I, Beesdo K, Gloster AT, Wittchen HU. Supplementary dimensional assessment in anxiety disorders. Int J Methods Psychiatr Res. 2007;16 Suppl 1(Suppl 1):S52-64. doi: 10.1002/mpr.215.

    PubMed 17623395

  • Roy-Byrne PP, Craske MG, Stein MB. Panic disorder. Lancet. 2006 Sep 16;368(9540):1023-32. doi: 10.1016/S0140-6736(06)69418-X.

    PubMed 16980119

  • Park YW, Choi D, Lee J, Ahn SS, Lee SK, Lee SH, Bang M. Differentiating patients with schizophrenia from healthy controls by hippocampal subfields using radiomics. Schizophr Res. 2020 Sep;223:337-344. doi: 10.1016/j.schres.2020.09.009. Epub 2020 Sep 26.

    PubMed 32988740

  • Park JE, Kim HS. Radiomics as a Quantitative Imaging Biomarker: Practical Considerations and the Current Standpoint in Neuro-oncologic Studies. Nucl Med Mol Imaging. 2018 Apr;52(2):99-108. doi: 10.1007/s13139-017-0512-7. Epub 2018 Feb 1.

    PubMed 29662558

  • Liang S, Ma A, Yang S, Wang Y, Ma Q. A Review of Matched-pairs Feature Selection Methods for Gene Expression Data Analysis. Comput Struct Biotechnol J. 2018 Feb 25;16:88-97. doi: 10.1016/j.csbj.2018.02.005. eCollection 2018.

    PubMed 30275937

  • Klauke B, Deckert J, Reif A, Pauli P, Domschke K. Life events in panic disorder-an update on "candidate stressors". Depress Anxiety. 2010 Aug;27(8):716-30. doi: 10.1002/da.20667.

    PubMed 20112245

  • Kim YW, Lee SH, Choi TK, Suh SY, Kim B, Kim CM, Cho SJ, Kim MJ, Yook K, Ryu M, Song SK, Yook KH. Effectiveness of mindfulness-based cognitive therapy as an adjuvant to pharmacotherapy in patients with panic disorder or generalized anxiety disorder. Depress Anxiety. 2009;26(7):601-6. doi: 10.1002/da.20552.

    PubMed 19242985

Questions about this trial

What is this clinical trial studying?

A study testing Mindfulness-based cognitive therapy using neuroscience (NMBCT) in people with Anxiety Depression, run by CHA University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 25 Aug 2023. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Hyun-Ju Kim, MD., PhD (82+31-780-5874, guswn10ve@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in GMV measured with sMRI (time frame: baseline, 8 weeks after treatment). The study lists 9 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05911412, which also lists 23 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Aug 2023.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in